Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours.
Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
Jazowiecka-Rakus
Joanna
J
Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.
Jarosz
Magdalena
M
Szala
Stanisław
S
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D037282:Calreticulin / Q000235:genetics*; D045744:Cell Line, Tumor; D003094:Collagen / Q000737:chemistry; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004338:Drug Combinations; D015316:Genetic Therapy / Q000379:methods*; D007797:Laminin / Q000737:chemistry; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic; D010446:Peptide Fragments / Q000235:genetics*; D010957:Plasmids / Q000378:metabolism; D011509:Proteoglycans / Q000737:chemistry; D014162:Transfection
D020533:Angiogenesis Inhibitors; D037282:Calreticulin; D004338:Drug Combinations; D007797:Laminin; D010446:Peptide Fragments; D011509:Proteoglycans; C121986:vasostatin; C059485:matrigel; D003520:Cyclophosphamide; D003094:Collagen